Calanolide A is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) first acquired from the Calophyllum lanigerum, variety austrocoriaceum, trees in the Malaysian state of Sarawak by botanist John Burley in 1987. The U.S. National Cancer Institute tested calanolide A as a possible cancer treatment, but had no effect. It was later found to have potent anti-HIV activity. On return trip to Malaysia, it was found that all of the austrocoriaceum variety tree species of Calophyllum lanigerum had been cut down most likely for fuel and building material in the swamp forest near Lundu where the first tree samples were taken; however, a few existing species were eventually located in the Singapore Botanic Garden. Since the plant source is relatively rare, a total synthesis was developed in 1996. The form in current use is formulated for oral administration and produced by Sarawak MediChem in Lemont, Illinois.

CAS：142632-32-4
中文别名：
英文别名：CALANOLIDE A;(+)-(10R,11S,12S)-12-HYDROXY-6,6,10,11-TETRAMETHYL-4-PROPYL-11,12-DIHYDRO-2H,6H,10H-BENZO(1,2-B:3,4-B\':5,6-B\'\']TRIPYRAN-2-ONE;calanolide-A;
分子式：C22H26O5
分子量：370.439
精确质量：370.178
Psa：68.9
Logp：4.3801

密度：1.181g/cm3
沸点：514.8ºC at 760mmHg
闪点：177.2ºC
折射率：1.558
蒸汽压：2E-11mmHg at 25°C